Vaccine production technology has evolved from using agents produced in animal tissue, eggs, and cultures to the use of virus-like particles (VLP). Challenges remain, however, in the analysis of key parameters for all types of vaccines. Many VLP vaccines can be characterized using techniques used for other biological drugs, however, more complex VLP vaccines offer unique analytical challenges.

As both vaccines and adjuvant development and production technologies have evolved, so too have the methodologies used to meet more demanding manufacturing and regulatory standards. In this webinar you will learn about the use of multiple biophysical and biochemical approaches for candidate vaccine characterization and analytical characterization of vaccine adjuvant molecules and formulations, including the use of HPLC with charged aerosol detection.

свернуть